SAN DIEGO, CA--(Marketwire - February 05, 2008) - Lpath, Inc. (OTCBB: LPTN), the category leader in therapeutic agents against bioactive lipids, today announced the FDA, after review of the company’s December 2007 Investigational New Drug (IND) submittal, has allowed the administration of ASONEP™ into human cancer patients in a Phase 1 clinical trial.
